ATE411019T1 - Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung - Google Patents

Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung

Info

Publication number
ATE411019T1
ATE411019T1 AT02725885T AT02725885T ATE411019T1 AT E411019 T1 ATE411019 T1 AT E411019T1 AT 02725885 T AT02725885 T AT 02725885T AT 02725885 T AT02725885 T AT 02725885T AT E411019 T1 ATE411019 T1 AT E411019T1
Authority
AT
Austria
Prior art keywords
carbonic acid
memory performance
improve learning
acid anhydrase
anhydrase activators
Prior art date
Application number
AT02725885T
Other languages
English (en)
Inventor
Daniel Alkon
Miao-Kun Sun
Original Assignee
Brni Neurosciences Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brni Neurosciences Inst filed Critical Brni Neurosciences Inst
Application granted granted Critical
Publication of ATE411019T1 publication Critical patent/ATE411019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AT02725885T 2001-05-02 2002-05-02 Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung ATE411019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28772101P 2001-05-02 2001-05-02

Publications (1)

Publication Number Publication Date
ATE411019T1 true ATE411019T1 (de) 2008-10-15

Family

ID=23104047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725885T ATE411019T1 (de) 2001-05-02 2002-05-02 Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung

Country Status (9)

Country Link
US (1) US20040235889A1 (de)
EP (1) EP1383497B1 (de)
JP (1) JP4824268B2 (de)
AT (1) ATE411019T1 (de)
AU (1) AU2002256422A1 (de)
CA (2) CA2744115A1 (de)
DE (1) DE60229371D1 (de)
ES (1) ES2314056T3 (de)
WO (1) WO2002087423A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
CA2574081A1 (en) * 2004-07-19 2006-02-23 University Of Florida Research Foundation, Inc. Methods and materials for treating mental illness
KR20090120480A (ko) 2007-02-09 2009-11-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 허혈/뇌졸중-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련된 물질의 치료학적 효과
EP3332797A3 (de) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen
HK1220622A1 (zh) * 2013-03-14 2017-05-12 Janssen Pharmaceutica, N.V. Gpr139的生理性配体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
RO86393B1 (ro) * 1983-04-19 1985-04-01 Gheorghe Danila Medicament cu actiune vasculo-trombocitara
WO1985003869A1 (en) * 1984-03-01 1985-09-12 Vernon Erk Method of treating memory disorders of the elderly
US6043270A (en) * 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US5955501A (en) * 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US5962498A (en) * 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US5891906A (en) * 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US5220068A (en) * 1986-09-25 1993-06-15 Chinoin Gyogyszer - Es Vegyeszeti Termekek Gyara Rt. Psychostimulant agent
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5359115A (en) * 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DE4232899C2 (de) * 1992-09-30 1995-02-23 Birkmayer Joerg Univ Prof Dr Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5362899A (en) * 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US5625232A (en) * 1994-07-15 1997-04-29 Texas Instruments Incorporated Reliability of metal leads in high speed LSI semiconductors using dummy vias
FI971995A7 (fi) * 1994-11-10 1997-05-09 Pfizer Makrosykliset laktoniyhdisteet ja niiden tuotantomenetelmä
US5944021A (en) * 1995-06-07 1999-08-31 Rodriguez; Victorio C. Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema
RU2115653C1 (ru) * 1995-12-27 1998-07-20 Иркутский институт органической химии СО РАН Комплексные соединения замещенных имидазолов, проявляющие антидотную и антигипоксантную активность
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
WO1999012901A1 (en) * 1997-09-08 1999-03-18 Georgetown University Substituted 2-pyrrolidinone activators of pkc
US5972684A (en) * 1997-11-25 1999-10-26 Incyte Pharmaceuticals, Inc. Carbonic anhydrase VIII
EP1844769A3 (de) * 1998-04-14 2010-02-10 The General Hospital Corporation Verfahren zur Behandlung neuropsychischer Erkrankungen
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
EP1181550A4 (de) * 1999-04-30 2005-03-02 Nathan S Kline Inst For Psychi Verfahren zum identifizieren von zusammenstellungen für die behandlung der alzheimerschen krankheit
WO2001093744A2 (en) * 2000-06-07 2001-12-13 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Controlling attention and memory by altering neuronal carbonic anhydrase activity
CA2394410A1 (en) * 2001-07-19 2003-01-19 Wilson Greatbatch Technologies, Inc. Insulative component for an electrochemical cell
TW201207390A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity

Also Published As

Publication number Publication date
CA2446074C (en) 2011-09-06
AU2002256422A1 (en) 2002-11-11
CA2446074A1 (en) 2002-11-07
WO2002087423A2 (en) 2002-11-07
CA2744115A1 (en) 2002-11-07
JP4824268B2 (ja) 2011-11-30
ES2314056T3 (es) 2009-03-16
EP1383497B1 (de) 2008-10-15
EP1383497A2 (de) 2004-01-28
DE60229371D1 (de) 2008-11-27
US20040235889A1 (en) 2004-11-25
WO2002087423A3 (en) 2003-02-27
JP2004535386A (ja) 2004-11-25
EP1383497A4 (de) 2005-12-14

Similar Documents

Publication Publication Date Title
NO20030900D0 (no) Peptidstrukturer nyttige for kompetitiv modulering av dipeptidyl peptidaseIV-katalyse
DE60221619D1 (de) Verfahren zur Reinigung von Synthesegas
WO2003072034A3 (en) Cyclic peptides and analogs useful to treat allergies
DE60315846D1 (de) Zusammenbau von chirurgischem klammerwerkzeug
DE602004023229D1 (de) Mais metallothionen promoter 2 und methoden zur verwendung
DE50213681D1 (de) Wässrige Lösung von Ascorbinsäure
DE60222042D1 (de) Herstellungsverfahren von Fahrzeugkarosserie-Seitenwänden
DE50302818D1 (de) Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
ATE411019T1 (de) Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
BRPI0515518A (pt) análogos de loxapina e métodos de usos dos mesmos
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60216641D1 (de) Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
DE60229194D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60321626D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60204584D1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
IS7281A (is) Umbrotsefni (3-{[4-tert-bútýl-bensýl)-(pýridín-3-súlfónýl)-amínó]-metýl}-fenoxý)-ediksýru
DE60300341D1 (de) Vorrichtung zur Behandlung von Abgas
DE502004003952D1 (de) Enzymatische herstellung von (meth)acrylsäureestern
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE60101461D1 (de) Verfahren zur katalytischen Zersetzung von Distickstoffmonoxid (N2O)
DE60315741D1 (de) Verfahren zur Herstellung von Acrylsäure
DE10195201T1 (de) Verfahren zur Herstellung von Kaliumfluorniobat-Kristallen sowie Kaliumfluorniobat-Kristalle
ATE513041T1 (de) Ghrelin bindende nukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties